MDGS.TASE

MDGS.Nasdaq

January 2018

Forward looking statements

This presentation may contain statements that are “Forward-Looking Statements,” which are based upon the

current estimates, assumptions and expectations of the company’s management and its knowledge of the

relevant market. The company has tried, where possible, to identify such information and statements by using

words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,”

“project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar

expressions and derivations thereof in connection with any discussion of future events, trends or prospects or

future operating or financial performance, although not all forward-looking statements contain these identifying

words. By their nature, Forward-Looking Statements involve uncertainties which may cause future results of the

company’s activity to differ significantly from the content and implications of such statements. Among the

factors which may cause the actual results to differ from the Forward-Looking Statements are changes in the

target market and the introduction of competitive products, regulatory, legislative and policy changes, and

clinical results. Forward-Looking Statements are pertinent only as of the date on which they are made, and the

company undertakes no obligation to update or revise any Forward-Looking Statements, whether as a result of

new information, future developments or otherwise. Nothing in this presentation should be deemed to be

medical or other advice of any kind.

Medigus – a compelling investment thesis

Flexible Endoscopic Surgery: Platform technology for minimally

invasive, trans oral approach for endoscopic procedures

Significant IP: Protecting global markets for flexible endoscopic

stapling, miniaturized visualization and integrated ultrasound

MUSE™ System is now Commercial: for minimally invasive reflux

surgery (GERD). FDA cleared, CE marked with initial revenue

Multiple Disease Indications: Large upper GI markets (GERD,

Obesity, GI cancer)for high gross margin, single-use devices

Medigus Commercial traction: Commercial use in US & EU, China

CFDA in process, ongoing camera revenue

Changing demographics driving global need

Upper GI diseases addressed; GERD, Obesity, GI Cancer

Obesity Western DietAging Population

• Strong regulatory foundation

• Critical KOL Support

• Peer review published data

• CMS Cat 1 reimbursement code

• Generating revenue in

commercial use

• Prototype complete

• Intellectual Property in place

• Animal testing complete

• Flexible stapling with integrated

visualization

• Fully integrated device

• Prototype complete

• Intellectual Property in place

• Flexible linear stapling device

with integrated visualization

GERD

MUSE™

GI

Cancer

ESD/EMR

Obesity

Flexible Linear Stapler

Medigus platform technologyFlexible Endoscopic Surgery

MUSE – Medigus Ultrasonic Surgical Endostapler

GERD – the condition

normal

sphincter

Stomach acid rises

through lax sphincter

Results in pain and possible

esophageal cancer

Current therapy:

drugs (PPIs) and/or surgery

• Huge market, but drugs don’t solve

underlying problem

• ~30% not satisfied with PPIs

• FDA warnings on chronic use

Medical

Treatment

GERD – existing treatments

8

Source: Gut. 2012; 61(4): 501-506

• Dysphagia, bloating and pain

are common

• Unpopular (<2% of patients)

• Laparoscopic surgical procedure

Surgical

Treatment

GERD transition in healthcare…..

1990s

Laparoscopic Surgery

1900s

Open Surgery

2017

Flexible Endoscopic Surgery

GERD – a global unmet need

Independent iData Research report (2012): US Market for Gastrointestinal Endoscopic Devices"

>60m potential patients with chronic GERD

7x increased probability of esophageal cancer from daily GERD

30% of PPI users not satisfied (woken up by GERD,

daily life impact)

Anti PPI trend• increased risk of hip, hand & spine fractures

• focal arrhythmias

• low magnesium levels

• associated with CDAD & dementia

>200k surgical procedures for chronic GERD

Treatment gap between PPI and surgery

Current Market

Severity of Symptoms and Dissatisfaction

High

GERD patients

Long term PPI use Surgery

Low

None treated

Ch

ron

ic G

ER

D

< 2%

Treatment gap between PPI and surgery

MUSE Upside

Severity of Symptoms and Dissatisfaction

GERD patients

SurgeryNone treated

Ch

ron

ic G

ER

D

High

GERD patients

MUSE™

Potential

Low

None treated Long term PPI use

Patient Market

>60 Million

MUSE fills the treatment gap

https://www.youtube.com/user/medigus2013

MUSE™ Flexible Endoscopic Surgery

Integrated ultrasound

Flexible, endoscopic staples

Optics are simply part of the device

Gen 8 MUSECommercial Ready!

• Chronic disease

• Medical therapy no

longer effective

• Not ready for surgery

• Less invasive alternative

Medigus value proposition – Flexible Endoscopic Surgery

• Offers a new surgical

product

• Alternative for

endoscopic surgeon

• Less invasive vs surgery

15

Gastroenterology Surgery

MUSE vs. Surgery

MUSE vs. Surgery

Direct vision as part of the endoscope, no other device needed

Single MD operation, no separate endoscope needed

Integrated ultrasound to visualize tissue

thickness for stapling accuracy

Standard surgical staples

durable and reliable

Flexible surgical endoscope

designed for single use

MUSE validation in peer review journals

4+ year follow-up on 37 of 69 patients in Pivotal Study

69% remained off PPI at 4 yrs.84% of this group were off PPI at 6 months

69-82% improvementIn GERD Health Related Quality of Life scores at

each time point

Results equal to or betterthan those for other devices for Endoluminal

GERD therapy

Early Revenue• $27m China Distribution Deal

• Germany, Italy, Spain

• Key US accounts

Single Use MUSE (US ASP $3,200)

Reimbursement

in Key Markets

Direct in

US & DE

Distributors in

IT & CN

China CFDA

Trial in Process

US & EU

Clinical Registry

Complete

KOLs Trained(currently in US, DE,

IT, IL, CH & CN)

MUSE is commercial ready

MUSE procedure progression

Dr. Ali Lankarani – Boreland Groover Group in Jacksonville, FL

Pre-Procedure Post-Procedure

1st Stapling

1

2nd Stapling

1

2

3rd Stapling

1

2

3

3rd Stapling

Medigus Platform

What’s next

Used for mucosal closure

Integrated flexible stapling device

Integrated micro camera

Support growing endoscopic

surgery platform

Proprietary technology with

dedicated IP

Flexible stapling

platform with camera

Medigus micro-ScoutCam

ATV-5 VIPIR robot

…is out of this world

the world’s smallest video camera…

World’s Smallest Camera

• 1.2mm total outer diameter

• 0.7 x 0.7mm proprietary sensor

• Up to 15m cable length

Applications for Visualization Technology

ScoutCam Currently used on

International Space StationMedical Applications:

• GI

• Pulmonology

• Cardiovascular

• ENT

• Neurosurgery

• Orthopedics

• Urology and Ob/Gyn

• Laparoscopic surgery and NOTES

• Robotic surgery

• Dental

Industrial Applications:

• Aerospace

• Nuclear InspectionNASA – VIPIR robot

Take Home Thoughts

Take home thoughts

Dedicated MUSE procedure reimbursement in US, Italy & Germany

Commercial MUSE traction; generating revenue in US & EU, China

CFDA in process, camera revenue ongoing

Large upper GI market opportunity, high gross margin & differentiated

platform technology for GERD, Obesity and GI Cancer

Compelling Medigus platform for Flexible Endoscopic Surgery

Strong intellectual property, over 70 issued patents

Strategic patent portfolio

70+ worldwide patents

Pate

• Endoscopic device having ultrasonic positioning (USA, Israel, Mexico, Canada)

• Transgastric method for carrying out a partial fundoplication (USA)

• Autoclavable imager assembly (USA, Australia, Israel, Canada)

• Stapling device (USA, Israel, Germany, UK, France, South Korea, Canada)

• Articulation section (USA, Israel)

• Endoscopic device comprising linear staplers and a video camera on its distal

end (USA)

• Method of performing surgical procedures on patients suffering from hiatal

hernia (USA)

• Multipurpose Endoscopy Suite (Germany, UK, Israel)

• Fundoplication apparatus and method (USA, S.Africa, Mexico, Israel, Japan,

Canada, UK, Germany, France, New Zealand)

• Stapler for endoscopes (USA, Australia, New Zealand, S.Africa, Mexico, Israel,

Japan, Canada, UK, Germany, France, Italy)

• Multiple view endoscopes (USA, Australia, New Zealand, S.Africa, Mexico,

Japan, Canada, UK, Germany, France, Italy)

• Small diameter video camera (Japan, US - for Medical Device and

Visualization Probes)

Pa

ten

t Su

mm

ary

Experienced leadership team

30

Mr. Birger served as Chairman and Director for Given Imaging Ltd. (publicly

traded NASDAQ and TASE) from June 2000 until February 2014, He also served

as Chief Executive Officer of Elron Electronic Industries, Ltd. (publicly traded

NASDAQ and TASE), or Elron, from August 2002 until April 2009.

Doron BirgerChairman

25 years of medical device senior leadership experience, including 17 years in

leadership roles at Boston Scientific Corporation; President Americas of Given

Imaging (recently acquired by Covidien for $860m); President of IntraPace.

Chris RowlandCEO

Over 20 years of experience in the high-tech medical device industry, with

expertise in marketing, sales, business development, and product management.

Prior to Medigus, Yaron held positions with Siemens, Given Imaging, MedSim and

NiTi Surgical Solutions.

Dr. Yaron SilbermanVP Sales & Marketing

Menashe has been CTO of Medigus since its establishment, and has been

responsible for the development of the MUSE™ device as well as the clinical trial

management. Menashe is a specialist in regulatory compliance and in design

control.

Menashe SonnenscheinVP Operations

Medigus Financial summary

31

Last cash position published (1)

As of Sep. 17 2017 ~ $5.8m

Number of employees As of Dec. 31 2017 27

Outstanding shares:As of Dec. 31 2017 191.8m

Outstanding shares - fully dilutedAs of Dec. 31 2017 351.7m

NASDAQ, TASE: MDGS

(1) Before the $1.6m fund raise on November 28th 2017

End